Einträge von Bernig, Toralf auf dem Publikationsserver

Corbacioglu, Selim , Lode, Holger, Ellinger, Susanne, Zeman, Florian, Suttorp, Meinolf, Escherich, Gabriele, Bochennek, Konrad, Gruhn, Bernd, Lang, Peter, Rohde, Marius, Debatin, Klaus Michael, Steinbach, Daniel, Beilken, Andreas, Ladenstein, Ruth, Spachtholz, Rainer, Heiss, Peter, Hellwig, Dirk , Tröger, Anja, Koller, Michael , Menhart, Karin , Riemenschneider, Markus J. , Zoubaa, Saida, Kietz, Silke, Jakob, Marcus, Sommer, Gunhild , Heise, Tilman , Hundsdörfer, Patrick, Kühnle, Ingrid, Dilloo, Dagmar, Schönberger, Stefan, Schwabe, Georg, von Luettichau, Irene, Graf, Norbert, Schlegel, Paul-Gerhardt, Frühwald, Michael, Jorch, Norbert, Paulussen, Michael, Schneider, Dominik T., Metzler, Markus, Leipold, Alfred, Nathrath, Michaela, Imschweiler, Thomas, Christiansen, Holger, Schmid, Irene, Crazzolara, Roman, Niktoreh, Naghmeh, Cario, Gunnar, Faber, Joerg, Demmert, Martin, Babor, Florian, Fröhlich, Birgit, Bielack, Stefan, Bernig, Toralf, Greil, Johann, Eggert, Angelika, Simon, Thorsten und Foell, Juergen (2024) Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology 25 (7), S. 922-932.

Seifert, Georg , Blakeslee, Sarah B. , Calaminus, Gabriele, Kandil, Farid I. , Barth, Andrea, Bernig, Toralf, Classen, Carl Friedrich, Corbacioglu, Selim, Föll, Jürgen, Gottschling, Sven, Gruhn, Bernd, vom Hoff-Heise, Claudia, Lode, Holger N. , Martin, David, Nathrath, Michaela, Neunhoeffer, Felix, Pekrun, Arnulf, Wulff, Beate, Zuzak, Tycho, Henze, Günter und Längler, Alfred (2022) Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up. BMC Cancer 22 (1). Volltext nicht vorhanden.